0000899243-20-026210.txt : 20200923
0000899243-20-026210.hdr.sgml : 20200923
20200923213537
ACCESSION NUMBER: 0000899243-20-026210
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200921
FILED AS OF DATE: 20200923
DATE AS OF CHANGE: 20200923
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ENRIGHT PATRICK G
CENTRAL INDEX KEY: 0001253886
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 201193406
MAIL ADDRESS:
STREET 1: CO LONGITUDE CAPITAL PARTNERS LLC
STREET 2: 800 EL CAMINO REAL, SUITE 220
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-21
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001253886
ENRIGHT PATRICK G
C/O LONGITUDE CAPITAL PARTNERS II, LLC
2740 SAND HILL ROAD, SECOND FLOOR
MENLO PARK
CA
94025
1
0
0
0
Common Stock, $0.0001 par value
2020-09-21
4
J
0
6113134
0.00
D
0
I
By: LVP2
Common Stock, $0.0001 par value
2020-09-21
4
J
0
91697
0.00
A
91697
I
By: LCP2
Common Stock, $0.0001 par value
78401
D
Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners II, L.P. ("LVP2") to its general and limited partners.
Reflects shares that were held by LVP2. Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LVP2. Each of LCP2 and the Reporting Person disclaim beneficial ownership over these securities and this report shall not be deemed an admission that either of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Represents a change in the form of ownership of LCP2 by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by LVP2.
Reflects shares held by LCP2. The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LCP2. The Reporting Person disclaims beneficial ownership over these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
/s/ Patrick G. Enright
2020-09-23